Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase | ACS Infectious Diseases
First Novel Antibiotic Since 20 Years, Gepotidacin Debuts To Treat Drug Resistance Urinary Tract Infections (UTIs) Amidst Growing Incidences! - Thailand Medical News
Antibiotics | Free Full-Text | Antibacterial Activity of the Novel Drug Gepotidacin against Stenotrophomonas maltophilia—An In Vitro and In Vivo Study
Pharmacokinetics, safety, and tolerability of gepotidacin administered as single or repeat ascending doses, in healthy adults and elderly subjects - Tiffany - 2022 - Clinical and Translational Science - Wiley Online Library
gepotidacin - Drug Hunter
Gepotidacin (GSK2140944) | Cas# 1075236-89-3 - GlpBio
Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections | Antimicrobial Agents and Chemotherapy
Intracellular concentration-response curves of gepotidacin (GEP)... | Download Scientific Diagram
Gepotidacin: New antibiotic appears to be effective against UTIs, company says | CNN
New Urinary Tract Infections Clinical Trial: Gepotidacin for Urinary Tract Infections - YouTube
TITLE PAGE
Dose Selection for Phase 3 Studies Evaluating Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections | GSK
Phase 2a Pharmacokinetic, Safety, and Exploratory Efficacy Evaluation of Oral Gepotidacin (GSK2140944) in Female Participants wi
Dose Selection for Phase 3 Studies Evaluating Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections | GSK
Novel drug gepotidacin for uncomplicated UTI meets trial goals
Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose- Ranging, Single-Oral Dose Eva
Dose Selection for a Phase 3 Study Evaluating Gepotidacin (GSK2140944) in the Treatment of Gonorrhoea | GSK
GSK to submit drug application for new antibiotic to US FDA - PMLiVE
Overview of microbiome dynamics during gepotidacin Phase 2a clinical... | Download Scientific Diagram
Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections | Antimicrobial Agents and Chemotherapy
Pharmacokinetics of Oral Formulations of Gepotidacin (GSK2140944), a Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor, in Healthy Adult and Adolescent Participants | Antimicrobial Agents and Chemotherapy
Design of Two Phase III, Randomized, Multicenter Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment of Uncomplicated Urinary Tract Infection in Female Participants | SpringerLink
Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase | ACS Infectious Diseases
Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose- Ranging, Single-Oral Dose Eva
GSK stops two Phase 3 studies for gepotidacin stopped early
Antibiotics | Free Full-Text | Pharmaceutical Approaches on Antimicrobial Resistance: Prospects and Challenges
